Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: PRIMMUNE THERAPEUTICS, INC.
Awarding agency: Department of Defense / Defense Threat Reduction Agency
Funding agency: Department of Defense / Defense Threat Reduction Agency
Period of performance: 2024-01-30 to 2025-08-25
Current total value of award: $10627894.87
Description: ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER.